Hepatocellular carcinoma (HCC)
Conditions
Interventions
Three times injection of chondroitin-glucuronate C5-epimerase-derived peptide after HCC local treatments every 2 weeks
Sponsors
Department of Gastroenterology, Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)HCC must be diagnosed 2)Karnofsky Performance Status is equal to or more than 70% 3)Patients must be equal to or more than 20 years old and written informed consent must be obtained 4)WBC is equal to or more than 2,000/mm3 5)Platelet is equal to or more than 50,000/mm3 6)Hb is equal to or more than 8.5 g/dl 7)Level of liver damage must be A or B 8)Serum Cr is equal to or less than 1.5 mg/dl
Exclusion criteria
Exclusion criteria: 1)Severe complications associated with heart, kidney, lung, blood and coagulability 2)Infection of HIV 3)Past medical history of malignancy 4)Surgical treatment, chemotherapy and radiation therrapy within 4 weeks 5)Past medical history of Immunodeficiency, splenectomy and radiation of spleen 6)medical treatments with steroid 7)Patients who are during lactation 8)Patients who are during pregnancy and expected pregnancy 9)Past history of organ transplantation 10)Patients who are predicted a difficulty of following clinical course 11)Patients who are judged inappropriate for clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of adverse events and immune responses | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of recurrence rate and tumor marker after HCC treatment | — |
Countries
Japan
Contacts
Public ContactEishiro Mizukoshi
Kanazawa University Hospital Department of Gastroenterology
Outcome results
None listed